Information updates

MyEpiPen® Patient Support Program

Australia’s 35,000-member EpiClub® program has been revamped and rebranded by Viatris (formerly Mylan) as the MyEpiPen® Patient Support Program.

Benefits for patients who join MyEpiPen® include:

  • Free EpiPen® trainer devices
  • Email and SMS reminder service for patients before their EpiPen® adrenaline (epinephrine) Auto-Injector devices expire.
  • ‘How to use’ cards to keep at home and share with others.
  • Video explainers in 26 languages that are appropriate for new patients and as refreshers for experienced patients.
  • Real-world patient videos in which parents and patients describe their experiences with using EpiPen® for first aid.
  • Evidence-based information to help people understand more about anaphylaxis and their EpiPen® Auto-Injectors.
  • Regular newsletters to keep patients up to date with relevant information.
  • Evidence-based information to help people understand more about anaphylaxis and their EpiPen® Auto-Injectors, with links to ASCIA anaphylaxis resources, such as the EpiPen® version of the ASCIA Action Plan for Anaphylaxis.
  • MyEpiPen® Welcome Kits which include the bag tag and wallet card that were developed by ASCIA after liaising with the team at Viatris. 

To access MyEpiPen® go to

Patients in New Zealand are currently on a separate EpiClub® NZ site, and will transition to  MyEpiPen® in the near future.

ASCIA 2021 Virtual Conference registered delegates can attend the following Viatris sponsored sessions, as shown on page 10 of the ASCIA 2021 Conference Program Book

Thursday 2nd September, 9-9.45 AEST, ‘Risk Multipliers for Anaphylaxis’ presented by Prof Pete Smith.

Friday 3rd September 9-9.45 AEST, ‘Classic Hayfever, Local Allergic Rhinitis and Nasal Hyper-Reactivity: Sorting out Nasal Symptoms and Treatments’ presented by Prof Richard Harvey.

Register for the ASCIA 2021 Virtual Conference at

Mod ASCIA Member
Donate to AIFA
go to NAC website

ASCIA is the peak professional body of clinical immunology and allergy in Australia and New Zealand
ASCIA promotes and advances the study and knowledge of allergy and other immune diseases

Quick Links


ASCIA is a registered trademark of the Australasian Society of Clinical Immunology and Allergy. All content is subject to copyright for the Australasian Society of Clinical Immunology and Allergy. Read more...

The content for the website is developed and approved by ASCIA Committee and ASCIA Working Party Members. Read more...

Disclaimer I Privacy

The ASCIA website is intended for use by ASCIA members, health professionals and the general public. The content provided is for education, communication and information purposes only and is not intended to replace or constitute medical advice or treatments. Read more...

ASCIA respects your privacy. Read our privacy policy here...

Sponsors | Advertising

ASCIA does not endorse products from sponsoring organisations, nor is it influenced by sponsoring organisations with regard to the content of education programs and websites. 

The ASCIA website does not accept advertising. Any link to a third-party website does not imply any endorsement by ASCIA.

Information Partner

Official Information Partner of Healthdirect Australia